Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,793 total articles

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Sep 3, 2026
Avery Klein
Press Releases

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics announced it will present new biomarker data demonstrating the immunomodulatory effects of its investigational drug cemsidomide, combined with dexamethasone, from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd International Myeloma Society Annual Meeting. The data highlights the drug's impact on T and NK cells, s…

CCCC
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Sep 3, 2026
Jordan Park
Press Releases

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

Eledon Pharmaceuticals announced multiple milestones for its lead drug candidate tegoprubart, including IND submission to FDA for an islet cell transplantation trial, enrollment of first patients in investigator-initiated studies, compassionate use dosing in transplant patients with renal dysfunction and high sensitization, and reaffirmed plans to …

ELDN
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Sep 3, 2026
Leila Farooq
Press Releases

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Fate Therapeutics announced management's participation in a fireside chat at the upcoming 2026 Annual Cantor Global Healthcare Conference to discuss its iPSC-derived off-the-shelf CAR T-cell product candidate FT819, recent clinical progress including the start of the Phase 2 RECLAIM-LN trial for lupus nephritis, and the unique safety profile of FT8…

FATE
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
Sep 3, 2026
Marcus Reed
Press Releases

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on innovative small molecule cancer treatments, will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted its leading programs including BH-30643, a Fast Track designated dr…

BLSM
ANI Pharmaceuticals to Present at September Investor Conferences
Sep 3, 2026
Avery Klein
Press Releases

ANI Pharmaceuticals to Present at September Investor Conferences

ANI Pharmaceuticals announced its participation in three upcoming investor conferences in September 2026, where its CEO and leadership team will present and engage in discussions. The conferences include the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Annual Global Investment Conference. These…

ANIP
Lands’ End Announces Second Quarter Fiscal 2026 Results
Sep 3, 2026
Marcus Reed
Press Releases

Lands’ End Announces Second Quarter Fiscal 2026 Results

Lands' End, Inc. (NASDAQ: LE) announced second quarter fiscal 2026 results highlighting a 2.7% increase in net revenue to $302 million driven by a 9% rise in U.S. eCommerce sales. The company reported net income of $3.5 million versus a loss in the prior year period, with gross margins improving by 320 basis points due in part to tariff refunds. Op…

LE
Duluth Holdings Inc. Announces Second Quarter 2026 Financial Results
Sep 3, 2026
Priya Menon
Press Releases

Duluth Holdings Inc. Announces Second Quarter 2026 Financial Results

Duluth Holdings Inc. announced robust financial results for its second quarter ended August 2, 2026, delivering a net income of $18.4 million, a marked increase from $1.3 million in the prior year's quarter. This improvement was largely driven by gross margin expansion aided by $16.3 million in tariff refunds and effective inventory management with…

DLTH
Amid AI Boom, Verisk Launches New View of U.S. Data Center Exposure, Helping Insurers Assess Growing Concentrations of Risk
Sep 3, 2026
Jordan Park
Press Releases

Amid AI Boom, Verisk Launches New View of U.S. Data Center Exposure, Helping Insurers Assess Growing Concentrations of Risk

Verisk has introduced a comprehensive U.S. Data Center Exposure Database designed to provide insurers, reinsurers, and brokers with detailed information about data center locations and characteristics, addressing the rapidly increasing concentration of risk due to AI-driven digital infrastructure expansion. This tool aims to improve underwriting, e…

VRSK
Reborn Coffee Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements
Sep 3, 2026
Maya Rios
Press Releases

Reborn Coffee Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements

Reborn Coffee Inc., a specialty coffee retailer listed on Nasdaq under ticker REBN, received a notice for failing to file its 10-Q report on time, placing it out of compliance with Nasdaq's listing rules. The company has 60 days to submit a plan to regain compliance and may be granted up to 180 additional days to file. There is no assurance the com…

REBN
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Sep 3, 2026
Priya Menon
Press Releases

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Biogen and Eisai announced that China's National Medical Products Administration has approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) for treating mild cognitive impairment and mild Alzheimer's dementia. This allows once-weekly at-home injections, offering a more convenient alternative to intravenous administration, and is …

BIIB
Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes
Sep 2, 2026
Jordan Park
Press Releases

Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes

Ming Shing Group Holdings Limited announced the closing of its acquisition of Meals Through Seasons Limited for USD 510 million, paid entirely in securities including 150 million Class A shares and USD 360 million in unsecured convertible promissory notes. The notes are structured with annual performance tranches tied to profit targets and have no …

PMA
Diversified Announces Accretive Acquisition of Birch
Sep 2, 2026
Priya Menon
Press Releases

Diversified Announces Accretive Acquisition of Birch

Diversified Energy Company (NYSE: DEC) has entered into definitive agreements to acquire Birch Permian Holdings for approximately $1.8 billion, marking its largest acquisition ever. The deal enhances Diversified's position as a major operator in the Permian Basin by increasing production by about 35% and adjusted EBITDA by approximately 55%. The ac…

DEC